NCT01011335View on ClinicalTrials.gov

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Staphylococcus Aureus
Interventions
BIOLOGICAL

Monovalent rAT

10, 25, 50 or 100 μg

BIOLOGICAL

Monovalent rLukS-PV

10, 25, 50 or 100 μg

BIOLOGICAL

Bivalent rLukS-PV / rAT

10, 25 or 50 μg

BIOLOGICAL

Placebo with adjuvant

Placebo with adjuvant

BIOLOGICAL

Placebo

Placebo saline

Trial Locations (2)

23708

Naval Medical Center Portsmouth, Portsmouth

78234

Brooke Army Medical Center, Fort Sam Houston

Sponsors

Collaborators (1)

Nabi Biopharmaceuticals
All Listed Sponsors
collaborator

Nabi Biopharmaceuticals

INDUSTRY

lead

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER

NCT01011335 - Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial | Biotech Hunter | Biotech Hunter